Published in Drug Week, December 3rd, 2004
These results include previously announced charges of $0.07 diluted earnings per share (DEPS) related to a legal settlement and certain inventory and fixed asset write-offs, all related to a U.S. generic nasal spray product. The company's guidance for the quarter was approximately break even.
Third quarter 2004 net revenues were $298 million, a decrease of 6% versus 2003. Excluding the impact of foreign currency, revenues declined 9%.
This revenue decline was due primarily to lower U.S. Human Pharmaceuticals revenues, partially offset...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week